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ABSTRACT
Hepatitis due to hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy is a serious 
cause of liver-related morbidity and mortality. Frequently used combination regimens in Non-Hodgkin’s lymphoma 
are cyclophosphamide, hydroxydaunomycin (adriamycin), vincristine (oncovin), and prednison (CHOP). The 
use of rituximab, a monoclonal antibody targeting CD20 antigen present in benign and malignant B-cells, in 
combination with systemic chemotherapy has resulted in an improved duration of remission and survival for 
this patients. Rituximab is a HBV reactivation risk factor even greater than corticosteroids in a series of patients 
with lymphoma treated with combined-modality treatment (CMT).
A 43 years old female patient who already diagnosed with Non-Hodgkin’s lymphoma, came with chief complain 
nausea and vomiting for three weeks. The patient recently got hospitalized with icteric and known have positive 
HBsAg. She received chemotherapy rituximab CHOP (R-CHOP) for four times and got rituximab in the last 
chemotherapy. Previously she had icteric and increased liver function test. After exclude other possibility causes 
this symptom and sign, it was concluded this is HBV reactivation. The chemotherapy was postponed until this 
reactivation of hepatitis B resolved and start giving lamivudine two weeks before reintroduce chemotherapy.
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ABSTRAK
Hepatitis dikarenakan reaktivasi virus hepatitis B (VHB) setelah pemberian terapi sitotoksik atau 
imunosupresi menyebabkan penyakit hati yang berhubungan dengan morbiditas dan mortalitas. 
Kombinasi regimen yang sering digunakan pada Non-Hodgkin’s lymphoma adalah cyclophosphamide, 
hydroxydaunomycin (adriamycin), vincristine (oncovin), and prednison (CHOP). Penggunaan rituximab, 
sebuah antibodi monoklonal dengan target CD20 yang ada pada sel B yang tidak ganas maupun ganas, 
dikombinasi dengan kemoterapi sistemik akan memperbaiki waktu remisi dan angka hidup pada pasien 
tersebut. Rituximab merupakan faktor resiko reaktivasi VHB yang lebih besar dari pada kortikosteroid 
pada beberapa kasus pasien dengan limfoma yang mendapat terapi kemoterapi.
Dilaporkan pasien wanita usia 43 tahun yang telah terdiagnosa limfoma Non-Hodgkin datang dengan 
keluhan mual dan muntah selama tiga minggu dan telah menjalani rawat inap karena ikterik dan diketahui 
HBsAg positif. Pasien ini telah menjalani kemoterapi rituximab-CHOP (R-CHOP) sebanyak empat kali dan 
rituximab ditambahkan pada kemoterapi terakhir. Pasien ini sebelumnya mengalami kuning dan terdapat 
peningkatan pemeriksaan fungsi hati. Setelah menyingkirkan kemungkinan lain penyebab gejala dan tanda 
tersebut, disimpulkan bahwa terdapat adanya reaktivasi VHB. Dilakukan penundaan kemoterapi hingga terjadi 
perbaikan dari reaktivasi hepatitis B tersebut dan dimulai pemberian lamivudin selama dua minggu sebelum 
diberikan kembali kemoterapi.
Kata kunci: terapi antivirus, kemoterapi, virus hepatitis B, reaktivasi
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INTRODUCTION
Reactivation of hepatitis B virus (HBV) which 
is stimulated by cytotoxic chemotherapy is a very 
important problem in patients with cancer. Increase in 
?????????????? ??????????????????????????????????????
and decompensated hepatitis and sometimes mortality 
is not rare when virus reactivation has started. HBV 
reactivation risk can be caused by patients' viral 
status and administered chemotherapy regiment. 
Chemotherapy regiment which consists of steroid 
and rituximab may increase risk virus reactivation in 
lymphoma patients. Therefore, HBV routine marker 
examinations are needed, including HBsAg and anti-
HBc which are indispensable in all cancer patients, and 
antivirus prophylaxis therapy is strongly recommended 
in positive HBsAg cases.1
CASE ILLUSTRATION
?????????????? ????? ????????????? ?????????????
lymphoma came to the outpatient clinic with complaints of 
nausea and yellow eyes since 4 weeks accompanied with 
brown colour urine. Previously, patient was hospitalized 
for three weeks due to nausea-vomiting and increased 
of absolute serum transaminase and serum bilirubin, 
including positive HBsAg were found. Patient was 
undergoing rituximab-cyclophosphamide-doxorubicin-
vincristine-prednison (R-CHOP) chemotherapy and 
??????????????? ?????????????????? ??????????????????
has no previous history of drug allergy. She got married 
????????????????????????????????????????????????????
had no previous history of jaundice. Previous history 
of free sex and intravenous drug abuse were denied by 
both, the patient and her family.
From physical examination, it was found that blood 
??????????????????????????????????????????????????
???????????? ???C. Other examinations resulted in 
anemic conjunctiva, icteric sclera and surgical scar in the 
abdomen area. Laboratory examination during her visit 
to the outpatient clinic revealed hemoglobin (Hb) 9.6 
?????? ????????????????????????????????? ?????????????
?????????? ????????????????????????????????? ??????????
?????????????????????????????????????????????????????
??????????????????? ?????????????????????????????????????
????????????????????? ??? ????????????? ??????????
positive anti HBe. This showed that patient had reached 
“immune restoration” phase.
????????????????????????????????????????????????
June, it was found that the liver function was within 
normal limits. At that moment, initial examination for 
???? ?????????????????? ?????? ???????????????????
chemotherapy in September, she was hospitalized due 
to the complaints of nausea, vomiting, and lethargy. 
Laboratory examinations revealed absolute increase 
??? ?????? ????????????? ???????????????????????????
???????????????????????????????????????????????????????
????? ??????????????????????????????????????????????
and positive HBsAg. 
In this patient, chemotherapy was planned to be 
postponed for up to 100 days after the presence of 
HBV infection reactivation until free disease and 
immune restoration phase occurred. Patient would 
receive prophylaxis with lamivudine 100 mg per day 
for one week before undergoing chemotherapy again 
up to  6-12 months after chemotherapy was completed.
Pasien was followed-up for approximately three 
months without chemotherapy or antiviral drugs. In 
this patient, clinical and laboratory improvements were 
obtained. There had been seroconversion of HBeAg 
to negative HBeAg and the presence of  anti-HBe. 
HBV DNA was not detected. HBsAg in the patient 
was still positive. Therefore, routine liver function 
and HBV DNA monitoring were still planned in this 
patient. Prophylaxis therapy would still be given in this 
????????????????????????????????????????????????????
before chemotherapy initiation up to 6-12 months after 
chemotherapy was completed.
DISCUSSION
HBV reactivation stimulated by immunosuppresive 
or cytotoxic chemotherapy drugs frequently occurs 
in HBV carrier and has wide range of symptoms, 
ranging from no symptoms to severe hepatitis with 
fatal complication. Reactivation does not occur only 
in positive HBsAg patients, but may also happen in 
???????????????????????? ???????????????? ?????????
as recovered hepatitis B case.1
Causes of HBV reactivation vary. Although 
reactivation may be spontaneous, most patients 
experienced virus infection reactivation due to 
???????????????????? ?????????? ????????????????????
host immune and HBV activation. This may happen 
due to administration of immunosuppressants, 
cytotoxic chemotherapy, HIV infection or sudden 
cessation of antiviral therapy. Number of virus will 
increase in this condition. Later, rebound immune 
response and hepatitis reaction happened after 
cessation of the therapy. 1
??? ????????????? ???????????? ?????????????? ????
???????????? ???????? ?????????? ??????????????? ??????
??? ?? ?????????????? ??? ????? ?????? ????????? ???
studies in HbsAg carrier, the average reactivation 
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???????????????????????????????????????????????
????????????????????????????????????????????????????
reactivation does not occur in all positive HBsAg 
carrier who underwent chemotherapy. Some risk 
factors of reactivation were male, young age, early high 
???? ???????????????????????? ?????????????????
positive HBeAg), administration of corticosteroid or 
rituximab chemotherapy regiment, and bone marrow 
transplant.2 HBV reactivation does not usually happen 
until the second or third cycle of chemotherapy 
administration. It is unclear if this is caused by virus or 
host factor.? One of the studies stated that the highest 
degree of HBV reactivation was found in lymphoma 
??????? ????????? ??????? ????????? ??? ??????? ???????
??????????????????????????????????????????????????????
????????????1 
Administration of rituximab has a higher risk factor 
of HBV reactivation as compared to corticosteroid. In 
several lymphoma patients who received chemotherapy, 
???? ????? ??????????? ??????????? ??????? ?????????????
between recovered hepatitis group and without 
reactivation group is the use of therapy with rituximab 
alone or in combination with steroid. Rituximab is a 
monoclonal anti-lymphocyte B antibody which causes 
apoptosis, and B cell plays important role in various 
response towards HBV, in addition to neutralizer 
antibody, cell B plays role as antigen precenting cell 
???? ????????????? ??????????????????????????????????
Therefore, B cell impairment may decrease immune 
response to HBV replication. This also explains the 
reason rituximab may cause fulminant hepatitis and 
?????????????????????? ?????????????? ?????????????????
in seroconversion cases.2 
???? ?????????? ??????? ????????????? ???????????
??? ?????????? ??????? ??? ???????? ?????????? ???????
reactivation is the presence of sudden increase in 
the number of serum HBV (more than 10 times) or 
reappearance of HBV DNA in the serum. Additionally, 
????????????????????????????????????????? ??? ?????????
????????????????????????????????????????????????????
?????????????? ???? ???????????????????????????? ???
reactivation, clinician has to exclude the proof of liver 
?????????????????????????????? ???????????????????????
drugs, newly administered transfusion, and systemic 
infection for all cases.4 HBV reactivation may be 
???????????????????????????????????????????????????????????
emergence of disease activity, and recovery.5
With routine serologic examination, it is currently 
known that liver impairment due to HBV reactivation 
passes through two phase process. Initially, during 
intensive cytotoxic or immunosuppressive therapy, 
there is increase of virus replication, described with the 
increase of serum HBV DNA, HBeAg, and HBV DNA 
polymerase due to infection expansion in the hepatocyte. 
Along with the recovery of immune function due to 
cessation of cytotoxic or immunosuppresive therapy, 
there will be rapid destruction mediated by immune to 
HBV infected hepatocyte, which clinically manifest as 
hepatitis, liver failure, or even death.? 
Nausea and vomiting are side effects of various 
drugs which usually occur at initial administration. 
Many factors play role in the appearance of severe 
symptoms in chemotherapy-induced nausea. Each 
????? ???? ???????? ??????????? ???????? ????????????
moderate, to severe). Depending on the chemotherapy 
agent, emitogenic potency may increase as the dose is 
increased. Cyclophosphamide emitogenic potency may 
be moderate to severe depending on the dose. When 
chemotherapy agents are given simultaneously with 
???????????????????????????????????????????????????
the emitogenic potency is higher compared to those 
agents administered alone. Chemotherapy-induced 
vomiting is usually more common to occur in female 
and young aged patients.6 In this patient, severe 
nausea-vomiting accompanied with increased liver 
transaminase and serum bilirubin were found. This 
showed the presence of liver impairment which 
underlied patient's complaint of nausea-vomiting, not 
only just due to chemotherapy agents.
Liver impairment during chemotherapy may not 
always describe hepatotoxicity from anti-cancer 
agents. Although many agents may cause liver 
impairment, most hepatotoxic reaction from drugs 
are idiosyncratic, due to immunologic reaction or 
variation of body metabolic response. This reaction 
particularly does not depend on the drug dose.7 Liver 
impairment mediated by immune may cause fever, 
skin redness, eosinophilia, and presence of antibody.? 
In this patient, there was no complaint of redness on 
skin, eosinophilia, or even positive autoantibody. 
Therefore, the initial diagnosis of serum transaminase 
due to chemotherapy agents could be kept aside.
Autoimmune hepatitis (AIH) is a disease with 
unknown etiology, with specific characteristic 
of presence of defect in suppressor T-cell with 
autoantibody which directly attack hepatocyte surface 
antigen. AIH predominantly attacks young and middle 
aged female. The presenting symptoms include 
fever, lethargy, skin redness, polyarthritis, pleuritis, 
pulmonary infiltration, or glomerulonephritis. In 
examination, there was increased liver transaminase, 
hypergammaglobulinemia, and positive autoantibody 
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(antinuclear antibody (ANA), smooth muscle antibody 
(SMA), or liver kidney microsomal type 1 (LKM1).9  
In this patient, there was no fever, skin redness, 
polyarthritis, pleuritis, or even glomerulonephritis. 
Autoantibody in this patient was negative. Therefore, 
the initial diagnosis of increased serum transaminase 
due to autoimmune hepatitis could be excluded.
HBV infection reactivation in asymptomatic 
hepatitis carrier patient who is undergoing chemotherapy 
has potency to have fatal complication. In previously 
healthy patient who suffered from acute hepatitis, 
????????? ????????????????????????????????????????????
antiviral therapy is not needed. In severe acute hepatitis 
which rarely happen, therapy using oral dose nucleoside 
analog, which is usually used for chronic hepatitis B 
therapy, may be performed with high success rate. 
Although through clinical research this has not been 
proven effective, acute and severe hepatitis B infection 
are still not indicated to be treated.10
In cases where HBV reactivation occur during 
chemotherapy, delaying cytotoxic therapy may be 
required up to 100 days, will give free disease phase 
and ability to survive generally in patients with 
malignancy who is associated with HBV reactivation. 
Mortality rate which is directly associated with HBV 
reactivation, secondary predominant to acute liver 
???????????????? ??????????? ???????? ????????????????
experienced reactivation during or associated with 
delaying chemotherapy, immunosuppressant, or other 
??????????????????????????????????????? ?????????????????
less effective. This is because of the treatment effect 
in inhibiting immune response which underlies liver 
impairment, thus treatment is usually ineffective.11,12
Based on the data and protocol from various 
studies, it is recommended that all HBsAg carrier 
?????????????????????????????????????????????????????
days before chemotherapy initiation.10,11 The duration 
of optimal lamivudine administration is still unclear, 
however it can be given 6-12 months after chemotherapy 
is completed to prevent delayed HBV reactivation.1,2,11 
Lamivudine is a nucleoside analog which is 
firstly approved to be used in the treatment of 
chronic hepatitis B. Prophylaxis effect of lamivudine 
in HBV reactivation in carrier hepatitis B during 
chemotherapy has been proven in two randomized 
studies (RCT). Incidence of HBV reactivation in 
lymphoma patients with positive HBsAg who received 
???????????????????????????????????????????????
??? ??????? ??? ???? ??? ?????????? ?????????? ??? ???????
acute hepatitis and mortality also decreased with 
lamivudine prophylaxis. HBV infection reactivation 
may also happen after completing chemotherapy and 
cessation of lamivudine prophylaxis, so it is known 
as delayed HBV reactivation, which rarely happens. 
Administration of preventive antiviral with adequate 
duration is very important in giving protective effect. 
Besides lamivudine, entecavir, telbivudine, and 
tenovovir are currently available for treatment of 
chronic hepatitis B and chemopreventive. Although 
the use of those prophylaxis antivirals are still limited.1 
????????????????????????????? ???????? ????? ????
American Association for the Study of Liver Disease 
(AASLD), the European Association for the Study of 
?????? ???????? ???????????????????????????? ???? ????
Study of Liver (APASL), HBV markers, including 
HBsAg and anti-HBc need to be evaluated in all cancer 
patients before chemotherapy is performed. To prevent 
HBV reactivation risk in carrier patient which can be 
life-threatening, antiviral therapy as routine prophylaxis 
is recommended in positive HBsAg patients before 
cancer chemotherapy is started. Duration of antiviral 
prophylaxis administration need to be prolonged for 
at least 6 months after therapy completion to prevent 
delayed HBV reactivation. Ideally antiviral prophylaxis 
therapy administration is continued until the end-point 
is achieved (seroconversion of HbeAg in positive 
HBeAg; the persistence of suppression of HBV DNA 
until not detected and disapperance of HBsAg in 
negative HBeAg patients), and this is recommended by 
AASLD to patients with initial high viral load (> 2000 
???????? ?????????????? ??????????????????????????????????
lamivudine or telbivudine may be used if the length of 
therapy is less than 12 months, or when HBV amount 
??? ??????????????????????????????? ??????????????????????
medicine, such as  entecavir or tenofovir can be used.1
There is still no recommendation made for the use of 
antiviral prophylaxis before chemotherapy in positive 
anti-HBc but negative HBsAg patients. However, HBV 
DNA need to be examined in positive anti-HBc patients 
without considering the anti-HBs status. Continuing 
HBV DNA examination need to be performed to detect 
the presence of HBV reactivation, and antiviral therapy 
need to be given as soon as possible if HBV DNA has 
????????????????????????????????????????????????????
ml during chemotherapy administration.1
In this patient, initial serologic examination towards 
hepatitis B before chemotherapy administration was 
not performed. After undergoing the fourth cycle 
of chemotherapy, there was complaints which are 
associated with the presence of acute hepatitis, increased 
absolute serum transaminase, hyperbilirubinemia, 
hypoalbuminemia, and thrombocytopenia. In that 
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fourth cycle, patient was given additional rituximab. 
During examination, she had positive HBsAg. After 
2 months, hepatitis B markers were evaluated; there 
was negative HBV DNA and negative HBeAg, 
which showed that there had been seroconversion 
without antiviral drug administration. After passing 
the acute hepatitis phase, we gave the patient antiviral 
prophylaxis with lamivudine 100 mg per day before the 
reinitiation of RCHOP chemotherapy for Non-Hodgkin 
lymphoma. Patient would be followed-up and routine 
examination of HBV DNA would be conducted until 
chemotherapy completion to see if there would still be 
HBV reactivation in this patient.
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